EU Extends Review of Teva, Cephalon Deal After Remedies

The European Commission extended its review of Teva Pharmaceutical Industries Ltd. (TEVA)’s bid for Cephalon Inc. (CEPH) after it was offered remedies to allay possible competition concerns over the deal.

The new deadline is Oct. 13, the commission said in a filing on its website today. It didn’t specify the remedies that were offered.

To contact the editor responsible for this story: Peter Chapman at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.